



UNIVERSITÄTS KLINIKUM HEIDELBERG

University Hospital Heidelberg

shipping address:
Lab of Complement Diagnostics
Dr. med. Jutta Schröder-Braunstein
Im Neuenheimer Feld 305
Room 220
69120 Heidelberg, Germany

Institute for Immunology,
Acting director: Prof. Dr. S. Meuer

Complement Analysis Laboratory Requisition

Ordering Physician:
Full Name, Clinic, Address incl. e-mail and Fax

Patient Surname

First Name

DOB

Gender

Address

HCN:

PAN:

Collection Date _____

Collection Time _____

Accession Nr. _____

Ministry of Health approval included

yes no

not applicable

Invoice to be sent to:

Report to be sent (if not to ordering physician)

Clinical diagnosis, treatments, special requests:

treatment with C5 Inhibitor: Eculizumab (Soliris®) yes no

Ravulizumab (Ultomiris®) yes no

current C3 concentration _____ g/l

Complement Analysis

(Informations: Phone +49 6221-564026/15, Fax +49 6221-565586/5536, www.klinikum.uni-heidelberg.de/diagnostik.143295.0.html)

Material: Serum EDTA-Plasma other body fluids (specify)

After separation of serum/EDTA-plasma from clot/cells transfer fluid to non-coated vials/tubes, freeze down to -70°C/-20°C and send per courier on dry ice

Complement Status: includes the analysis of global functions of the classical/CH50 and alternative/AH50 pathways (serum), as well as the activation products C3d and sC5b-9 (EDTA-plasma), recommended for general screening and monitoring

Protein Analysis: C1q C3 C4 C3d Factor B Factor D

Factor H Factor I Properdin MBL (Mannose Bind. Lectin)

Functional Analysis: Class. Pathway (CH 50) Altern. Pathway (AH50) Lectin Pathway

Titration of individual components (only upon specific request) C1-C9

sC5b-9 (only in EDTA-plasma)

Autoantibodies: C3 Nephritic Factor (only in serum) Auto-anti-Factor H Auto-anti-C1q Auto-anti-C1 Inhibitor

aHUS - Panel (CH50, APH50, C3d, sC5b-9, C3, auto-anti-FH)

MPGN - Panel (CH50, APH50, C3d, sC5b-9, C3, C3 Nephritic Factor)

Nephritic - Panel (CH50, APH50, C3d, sC5b-9, C3, C3 Nephritic Factor, auto-anti FH)

C5 inhibitor monitoring: complement inhibition: includes CH50, APH50, C3d, sC5b-9

serum concentration: Eculizumab® Ravulizumab®

